Knight Therapeutics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022
For the nine months, sales was CAD 211.91 million compared to CAD 185.21 million a year ago. Net loss was CAD 14.7 million compared to net income of CAD 23.98 million a year ago. Basic loss per share from continuing operations was CAD 0.13 compared to basic earnings per share from continuing operations of CAD 0.19 a year ago. Diluted loss per share from continuing operations was CAD 0.13 compared to diluted earnings per share from continuing operations of CAD 0.19 a year ago.